BridgeBio Pharma reports primary endpoint achieved in 76% of CALIBRATE patients
A presentation on encaleret reports that 76% of patients in the CALIBRATE study achieved the primary endpoint.
A presentation on encaleret reports that 76% of patients in the CALIBRATE study achieved the primary endpoint.